CFDE Data Portal | Search PPP1R11

	Label	Description
	PPP1R11 associations Collection (Entity type)	Associations for PPP1R11_associations
	PPP1R11 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	PPP1R11 Gene (Entity type)	ENSG00000204619 - protein phosphatase 1 regulatory inhibitor subunit 11
	GSE128730 3 V 5 NERATINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 6 v 11 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE229973 3 V 2 CISPLATIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE199107 tryptophan 6 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE213588 trametinib NF1 9 v 12 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE228017 parthenolide 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE104022 1 V 0 TAMOXIFEN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS

PPP1R11 associations

Associations for PPP1R11_associations

PPP1R11 associations.tsv

A file from IDG as part of the Harmonizome project

PPP1R11

ENSG00000204619 - protein phosphatase 1 regulatory inhibitor subunit 11

GSE128730 3 V 5 NERATINIB HUMAN UP

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 6 v 11 human up

A Gene Set from LINCS

GSE229973 3 V 2 CISPLATIN HUMAN DN

A Gene Set from LINCS

GSE199107 tryptophan 6 v 7 human up

A Gene Set from LINCS

GSE213588 trametinib NF1 9 v 12 human dn

A Gene Set from LINCS

GSE228017 parthenolide 0 v 1 human up

A Gene Set from LINCS

GSE104022 1 V 0 TAMOXIFEN MOUSE DN

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.